Cenegermin for Corneal Ulcer

This trial tests cenegermin, an eye drop treatment, to determine its effectiveness in healing persistent corneal epithelial defects (PCED), which are stubborn, non-healing sores on the cornea. The goal is to see if cenegermin can completely heal these defects within four weeks. Participants will receive either the cenegermin drops or a placebo (inactive solution) to compare results. Suitable candidates for this trial are adults who have had PCED for at least two weeks without improvement from standard treatments like eye lubricants. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking treatment.

The trial allows the use of most topical eye medications if you've been on a stable dose for at least 30 days and don't plan to change it during the study. However, certain medications like high-dose systemic corticosteroids, systemic opioids, and some eye drops must be stopped before joining. Check with the trial team for specifics on your medications.

Studies have shown that cenegermin is generally well-tolerated by patients. Research indicates that the most common side effects include eye pain, irritation, and redness. Specifically, 47% of patients reported eye pain, while 14% experienced eye irritation. These side effects are usually manageable and do not require stopping treatment.

Unlike the standard of care for corneal ulcers, which often includes antibiotic eye drops and sometimes surgery, cenegermin is unique because it uses a nerve growth factor to promote healing. This treatment has the potential to regenerate corneal tissue, directly targeting the underlying cause of the ulcer rather than just managing symptoms. Researchers are excited about cenegermin because it offers a novel approach that could not only speed up recovery but also improve overall eye health in ways current treatments cannot.

Research has shown that cenegermin can help heal corneal ulcers. In earlier studies, 67% of patients had their eye surface fully healed by week 8. Another study found that 22 out of 26 patients had completely healed corneal ulcers in the same period. Cenegermin is already approved for treating neurotrophic keratopathy, a similar eye condition, demonstrating its ability to improve eye health and sensation. In this trial, participants will receive either cenegermin or a vehicle ophthalmic solution at random. These studies suggest cenegermin could be a promising treatment for corneal ulcers.⁶⁷⁸⁹¹⁰